Immuron (IMRN) Long-Term Investments (2022 - 2023)
Immuron (IMRN) recorded quarterly Long-Term Investments of $1590.7 in Q4 2023, down 98.47% quarter-over-quarter from $104264.5 in Q3 2023, and down 22.5% on a YoY basis from $2052.4 in Q4 2022.
Immuron (IMRN) Long-Term Investments (2022 - 2023) Analysis & Trends
Immuron's Long-Term Investments history runs 2 years deep, the most recent figure standing at $1590.7 for Q4 2023.
- In Q4 2023, Long-Term Investments fell 22.5% year-over-year to $1590.7; the TTM figure through Dec 2023 stood at $1590.7 (down 22.5% YoY), while the FY2023 annual figure was $1590.7, down 22.5% from the prior year.
- Long-Term Investments was $1590.7 for Q4 2023 at Immuron, down from $104264.5 in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $106313.4 in Q2 2023 to a low of $1590.7 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immuron | 921.61 Mn | 921.58 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,590.66 |
| Sep 28, 2023 | 104,264.55 |
| Aug 30, 2023 | 1,590.66 |
| Jun 30, 2023 | 106,313.42 |
| Dec 31, 2022 | 2,052.41 |